AbbVie Inc. $ABBV Position Reduced by LaFleur & Godfrey LLC

LaFleur & Godfrey LLC cut its holdings in AbbVie Inc. (NYSE:ABBV) by 4.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 69,574 shares of the company’s stock after selling 3,545 shares during the period. AbbVie makes up 2.2% of LaFleur & Godfrey LLC’s portfolio, making the stock its 13th largest position. LaFleur & Godfrey LLC’s holdings in AbbVie were worth $18,200,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. North Dakota State Investment Board grew its stake in shares of AbbVie by 3.9% in the third quarter. North Dakota State Investment Board now owns 54,228 shares of the company’s stock worth $14,186,000 after purchasing an additional 2,031 shares during the last quarter. Beacon Bank & Trust lifted its holdings in AbbVie by 6.8% in the third quarter. Beacon Bank & Trust now owns 4,431 shares of the company’s stock worth $1,159,000 after buying an additional 282 shares during the period. Lynx Investment Advisory lifted its holdings in AbbVie by 12.9% in the third quarter. Lynx Investment Advisory now owns 3,318 shares of the company’s stock worth $868,000 after buying an additional 380 shares during the period. AMI Investment Management Inc. purchased a new stake in AbbVie in the third quarter worth about $245,000. Finally, Sigma Investment Counselors Inc. boosted its position in AbbVie by 10.6% during the 3rd quarter. Sigma Investment Counselors Inc. now owns 34,537 shares of the company’s stock valued at $9,034,000 after acquiring an additional 3,299 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Price Performance

Shares of NYSE ABBV opened at $286.10 on Thursday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $291.40. The stock has a market cap of $505.47 billion, a P/E ratio of 80.82, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24. The firm has a 50-day moving average of $268.20 and a 200 day moving average of $236.51.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts expect that AbbVie Inc. will post 13.92 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ABBV shares. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Bank of America reissued a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and raised their target price for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. Cantor Fitzgerald lifted their price target on AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. Finally, Morgan Stanley upped their price target on AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $279.86.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted a Biologics License Application to the FDA for etentamig, a monthly-dosed BCMA x CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. The Phase 3 CERVINO study reportedly delivered statistically significant improvements in overall response rate and progression-free survival versus standard therapies, adding a potential growth product to AbbVie’s oncology pipeline. AbbVie Submits BLA for Etentamig
• Positive Sentiment: AbbVie’s growth drivers remain in focus. Skyrizi and Rinvoq are expected to help offset Humira’s decline, while the FDA’s approval of a subcutaneous induction option for Skyrizi in Crohn’s disease could improve convenience and broaden adoption through at-home treatment. Skyrizi Crohn’s Disease Approval
• Neutral Sentiment: Investors are preparing for AbbVie’s third-quarter results, with attention on Skyrizi and Rinvoq sales, expense trends, updated guidance, and the sustainability of earnings growth. The company previously reported quarterly revenue and adjusted earnings above consensus expectations.
• Negative Sentiment: Analysts continue to debate whether ABBV is fully valued after a strong rally. Its elevated valuation leaves less room for disappointment, while rising expenses, softer estimates, and intensifying competition could pressure near-term results. AbbVie Patent Cliff Analysis
• Negative Sentiment: The company’s dividend appeal faces a longer-term test as investors seek evidence that Skyrizi and Rinvoq can replace lost Humira revenue and support continued payout growth. High Treasury yields also make income-oriented stocks compete harder for investor capital.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.